


# PRODUCT INFORMATION



REV 5901

Item No. 70600

CAS Registry No.: 101910-24-1  
Formal Name: a-pentyl-3-(2-quinolinylmethoxy)-benzenemethanol  
MF: C<sub>22</sub>H<sub>25</sub>NO<sub>2</sub>  
FW: 335.4  
Purity: ≥98%  
Supplied as: A crystalline solid  
Storage: -20°C  
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

REV 5901 is supplied as a crystalline solid. A stock solution may be made by dissolving the REV 5901 in the solvent of choice, which should be purged with an inert gas. REV 5901 is soluble in organic solvents such as ethanol, methanol, acetone, DMSO, and acetonitrile. The solubility of REV 5901 in these solvents is approximately 100 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Also, ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

## Description

REV 5901 has been shown to be a competitive antagonist of peptidoleukotrienes. *In vitro*, it has a K<sub>i</sub> value of 0.7 μM vs. [<sup>3</sup>H]Leukotriene D<sub>4</sub> (LTD<sub>4</sub>) binding to membranes from guinea pig lung.<sup>1</sup> It is an antagonist of LTC<sub>4</sub>-induced contraction of guinea pig lung parenchymal strips with an IC<sub>50</sub> of 3.6 μM and exhibits 91% inhibition of SRS-A mediated bronchospasm in the guinea pig *in vivo* at 10 mg/kg administered intraduodenally.<sup>2</sup> REV 5901 is a potent inhibitor of rat neutrophil 5-lipoxygenase with an IC<sub>50</sub> of 0.12 μM.<sup>2</sup> The release of PAF by peritoneal mast cells could be inhibited by REV 5901 in a concentration-dependent manner (IC<sub>50</sub> = 3.9 μM).<sup>3</sup>

## References

1. Van Inwegen, R.G., Khandwala, A., Gordon, R., *et al.* REV 5901: An orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. *J. Pharmacol. Exp. Ther.* **241**, 117-124 (1987).
2. Musser, J.H., Charkraborty, U.R., Sciortino, S., *et al.* Substituted arylmethyl phenyl ethers. 1. A novel series of 5-lipoxygenase inhibitors and leukotriene antagonists. *J. Med. Chem.* **30**, 96-104 (1987).
3. Hogaboam, C.M., Donigi-Gale, D., Shoupe, T.S., *et al.* Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds. *Br. J. Pharmacol.* **105**, 87-92 (1992).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2023

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM